Altea Therapeutics is developing and commercializing initial products with leading pharmaceutical companies and has partnered with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company to develop and commercialize a novel daily transdermal patch delivering sustained levels of exenatide (currently marketed as Byetta®). The Company also has a partnership with Hospira, Inc. to develop and commercialize a transdermal patch for delivering enoxaparin sodium (currently marketed as Lovenox®) utilizing the PassPort® Transdermal Delivery System.
Most recently, Altea Therapeutics announced a partnership with KAI Pharmaceuticals, Inc. for the preclinical and clinical development of certain KAI proprietary peptides utilizing Altea’s proprietary transdermal technology. Additionally, Altea Therapeutics is partnered with several pharmaceutical companies to conduct feasibility studies on certain proprietary compounds.
The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment